Dominari (DOMH) Competitors $6.35 -0.02 (-0.31%) As of 09:47 AM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock DOMH vs. VNDA, IRWD, CDXS, CBIO, SGMO, ACHV, AGEN, FBIO, SABS, and CRISShould you be buying Dominari stock or one of its competitors? The main competitors of Dominari include Vanda Pharmaceuticals (VNDA), Ironwood Pharmaceuticals (IRWD), Codexis (CDXS), Crescent Biopharma (CBIO), Sangamo Therapeutics (SGMO), Achieve Life Sciences (ACHV), Agenus (AGEN), Fortress Biotech (FBIO), SAB Biotherapeutics (SABS), and Curis (CRIS). These companies are all part of the "biotechnology" industry. Dominari vs. Its Competitors Vanda Pharmaceuticals Ironwood Pharmaceuticals Codexis Crescent Biopharma Sangamo Therapeutics Achieve Life Sciences Agenus Fortress Biotech SAB Biotherapeutics Curis Dominari (NASDAQ:DOMH) and Vanda Pharmaceuticals (NASDAQ:VNDA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations, valuation and media sentiment. Do analysts prefer DOMH or VNDA? Vanda Pharmaceuticals has a consensus price target of $16.50, indicating a potential upside of 204.43%. Given Vanda Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Vanda Pharmaceuticals is more favorable than Dominari.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dominari 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Vanda Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67 Which has more volatility and risk, DOMH or VNDA? Dominari has a beta of 0.75, indicating that its share price is 25% less volatile than the S&P 500. Comparatively, Vanda Pharmaceuticals has a beta of 0.74, indicating that its share price is 26% less volatile than the S&P 500. Does the media favor DOMH or VNDA? In the previous week, Dominari and Dominari both had 4 articles in the media. Dominari's average media sentiment score of 0.67 beat Vanda Pharmaceuticals' score of 0.20 indicating that Dominari is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dominari 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vanda Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is DOMH or VNDA more profitable? Vanda Pharmaceuticals has a net margin of -32.90% compared to Dominari's net margin of -36.01%. Vanda Pharmaceuticals' return on equity of -12.89% beat Dominari's return on equity.Company Net Margins Return on Equity Return on Assets Dominari-36.01% -94.32% -78.21% Vanda Pharmaceuticals -32.90%-12.89%-10.47% Do insiders and institutionals believe in DOMH or VNDA? 42.5% of Dominari shares are owned by institutional investors. Comparatively, 88.1% of Vanda Pharmaceuticals shares are owned by institutional investors. 33.0% of Dominari shares are owned by insiders. Comparatively, 10.0% of Vanda Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has stronger valuation & earnings, DOMH or VNDA? Dominari has higher earnings, but lower revenue than Vanda Pharmaceuticals. Vanda Pharmaceuticals is trading at a lower price-to-earnings ratio than Dominari, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDominari$18.15M5.45-$14.70M-$2.37-2.69Vanda Pharmaceuticals$198.77M1.61-$18.90M-$1.13-4.80 SummaryVanda Pharmaceuticals beats Dominari on 10 of the 16 factors compared between the two stocks. Get Dominari News Delivered to You Automatically Sign up to receive the latest news and ratings for DOMH and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DOMH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DOMH vs. The Competition Export to ExcelMetricDominariMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$98.99M$2.65B$6.15B$10.63BDividend YieldN/A56.68%5.66%4.69%P/E Ratio-2.6923.7585.8827.64Price / Sales5.45636.66592.82189.98Price / CashN/A177.3038.3262.20Price / Book1.125.6413.006.79Net Income-$14.70M$32.78M$3.30B$275.88M7 Day Performance-12.62%5.19%3.68%1.84%1 Month Performance-4.21%14.48%10.67%8.84%1 Year Performance251.91%3.73%84.00%36.10% Dominari Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DOMHDominari0.6329 of 5 stars$6.35-0.3%N/A+237.0%$98.68M$18.15M-2.684News CoverageAnalyst ForecastVNDAVanda Pharmaceuticals4.109 of 5 stars$5.32-1.5%$16.50+210.2%+21.9%$314.36M$198.77M-4.71290Analyst ForecastIRWDIronwood Pharmaceuticals4.4837 of 5 stars$1.52+2.7%$4.94+225.0%-58.0%$246.90M$308.52M-30.39220News CoveragePositive NewsAnalyst ForecastCDXSCodexis3.0902 of 5 stars$2.56-4.8%$11.00+329.7%-13.3%$231.08M$57.16M-3.08250Analyst ForecastGap UpCBIOCrescent Biopharma4.4002 of 5 stars$11.29-2.7%$25.60+126.7%N/A$220.72MN/A-0.3250Positive NewsHigh Trading VolumeSGMOSangamo Therapeutics2.2225 of 5 stars$0.70-0.2%$4.50+544.9%-6.5%$210.53M$81.71M-2.41480News CoverageAnalyst ForecastACHVAchieve Life Sciences2.6213 of 5 stars$3.32+5.1%$12.00+261.4%-35.9%$169.65MN/A-2.2720Analyst ForecastAGENAgenus4.3886 of 5 stars$4.25+2.4%$14.50+241.2%-8.6%$135.41M$103.46M-0.59440Analyst ForecastFBIOFortress Biotech2.5969 of 5 stars$3.05-1.9%$16.50+441.0%+77.2%$90.74M$57.67M-2.90170Analyst ForecastSABSSAB Biotherapeutics4.1884 of 5 stars$2.34+2.2%$9.75+316.7%-7.4%$24.36M$1.32M-0.59140CRISCuris2.2353 of 5 stars$1.62-2.4%$17.00+949.4%-68.1%$20.25M$10.91M-0.3360Analyst Forecast Related Companies and Tools Related Companies Vanda Pharmaceuticals Competitors Ironwood Pharmaceuticals Competitors Codexis Competitors Crescent Biopharma Competitors Sangamo Therapeutics Competitors Achieve Life Sciences Competitors Agenus Competitors Fortress Biotech Competitors SAB Biotherapeutics Competitors Curis Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DOMH) was last updated on 10/10/2025 by MarketBeat.com Staff From Our Partners"I'm risking my reputation on this"The Fed rate cut truth they don't want you to know The Fed's 25 basis point cut isn't just monetary policy…...Crypto 101 Media | SponsoredBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredElon Warns “America Is Broke”. Trump’s Plan Inside.For the everyday American who's worked hard to build their nest egg, Trump preserved a IRS loophole that allow...American Hartford Gold | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dominari Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dominari With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
